DC
VRTX icon

Davenport & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Davenport & Co’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,000
Closed -$290K – 1048
2022
Q3 		$290K Sell
1,000
-500
-33% -$144K ﹤0.01% 823
2022
Q2 		$423K Sell
1,500
-300
-17% -$80.3K ﹤0.01% 725
2022
Q1 		$470K Hold
1,800
– – ﹤0.01% 750
2021
Q4 		$395K Buy
+1,800
New +$350K ﹤0.01% 820

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
MLL
Moody Lynn & Lieberson Boston, Massachusetts $1.9B AUM 27.82% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
P
PensionDanmark Copenhagen O, Denmark $12B AUM

Davenport & Co's VRTX Position: Q2 2026 in Review

Davenport & Co reduced its Vertex Pharmaceuticals (VRTX) stake by 1.4% in Q2 2026, selling an estimated $1.35M and leaving 207,108 shares worth $103M. The position accounts for 0.51% of the portfolio, ranked #59.

Davenport & Co first reported a position in VRTX in Q3 2020 and has held it in 24 quarters since. The position peaked at $110M in Q1 2025. 296 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Davenport & Co held 207,108 shares of Vertex Pharmaceuticals worth $103M as of Q2 2026.
  • Davenport & Co sold 3,044 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.35M.
  • Vertex Pharmaceuticals made up 0.51% of Davenport & Co's portfolio in Q2 2026, its #59 holding.
  • Davenport & Co first reported a position in Vertex Pharmaceuticals in Q3 2020 and has held it in 24 quarters since.
  • Davenport & Co's Vertex Pharmaceuticals position peaked at $110M in Q1 2025.
  • 296 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Davenport & Co's 13F filing for Q2 2026, filed 13 Jul 2026.